CENTOGENE has entered into an agreement with Aldeyra Therapeutics Inc., a biotechnology company developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Under the terms of the agreement, CENTOGENE will collaborate with Aldeyra to globally identify patients with SLS and to understand the clinical spectrum of this disease. The goal of the agreeement is to support physicians and patients with early diagnosis through genetic testing that could potentia...